What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2021-08-16 compared with 2021-05-14 · 195 added, 19 removed, 0 unchanged (100% of the section changed)

were no material changes from the risk factors set forth under Part I, Item 1A., “Risk Factors”

in our Annual Report on Form

10-K for the fiscal year ended December 31, 2020.

You should carefully consider these factors in addition to the other information

set forth in this report which could materially affect our business, financial condition or future results.

The risks and uncertainties

described in this report and in our Annual Report on Form 10-K for the year ended December 31, 2020, as well as other reports and

statements that we file with the SEC, are not the only risks and uncertainties facing us.

Additional risks and uncertainties not currently

known to us or that we currently deem to be immaterial may also have a material adverse effect on our financial position, results of

operations or cash flows.

the COVID-19 outbreak, some tenants have delayed on rent payment.

Our general development operations have continued during the COVID-19

pandemic and we have not had significant disruption.

Currently we are unable to accurately predict the future impact of COVID-19 due

to the developing circumstances and uncertainty surrounding this current pandemic, including the ultimate geographic spread of COVID-19,

the severity of the disease, the duration of the outbreak, and effectiveness of the actions that may be taken by governmental authorities.

Our management has been closely monitoring the impact caused by COVID-19 and we will continue to operate our business as steadily and

safely as we can.

Except for the

additional risk factors addressed below, there were no material changes from the risk factors set forth under Part I, Item 1A., “Risk

Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

You should carefully consider these

factors in addition to the other information set forth in this report which could materially affect our business, financial condition

or future results.

The risks and uncertainties described in this report and in our Annual Report on Form 10-K for the year ended December 31,

2020, as well as other reports and statements that we file with the SEC, are not the only risks and uncertainties facing us.

risks and uncertainties not currently known to us or that we currently deem to be immaterial may also have a material adverse effect on

our financial position, results of operations or cash flows.

general development operations have continued during the COVID-19 pandemic and we have not had significant disruption.

Currently we are

unable to accurately predict the future impact of COVID-19 due to the developing circumstances and uncertainty surrounding this current

pandemic, including the ultimate geographic spread of COVID-19, the severity of the disease, the duration of the outbreak, and effectiveness

of the actions that may be taken by governmental authorities.

Our management has been closely monitoring the impact caused by COVID-19

and we will continue to operate our business as steadily and safely as we can.

We have entered into two third-party research

agreements to advance our sponsored research programs.

These arrangements may not ultimately yield any promising product candidates for

preclinical or clinical development.

We may not be able to fully realize the benefits of any intellectual property generated by these

arrangements.

Part of our strategy involves collaborative sponsored

research to be performed by third-party research institutions.

Avalon has entered into various research agreements including an agreement

with Massachusetts Institute of Technology (MIT) to research novel therapeutic and diagnostic targets development utilizing QTY-code protein

design technology including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine

Storm Strategic as well as a partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop

an S-layer vaccine that can be administered by an intranasal or oral route against SARS-CoV-2, the novel coronavirus that causes COVID-19

Although we seek

to direct this research and advise on the design of these projects as well as critical development decisions, this research is being performed

by individuals who are not our employees and the timeline and quality of the research efforts are outside of our direct control.

investigators and other researchers may have different priorities than we do as a CellTech bio-developer.

The sponsored research agreements

we enter into for these programs generally provide that any inventions resulting from the research will be owned by the research institution

performing the research, and that we have an option to negotiate for a license to develop and exploit any such inventions.

information and new inventions derived from these research efforts may be disclosed through publications or other means prior to our third-party

research collaborators being able to protect such intellectual property through the filing of patent applications.

Our third-party research

collaborators may not be able to obtain or maintain full ownership of inventions that are derived from the research or associated rights,

which may limit their ability to provide us with a license to all relevant intellectual property on terms and conditions that are acceptable

Even if our collaborative research efforts yield promising results or new technological advances, they may not ultimately result

in our being able to protect, develop or exploit the resulting intellectual property.

Risks Related

to the VIE Structure and SenlangBio being a PRC Domestic Entity

are uncertainties regarding the interpretation and enforcement of PRC laws, rules, and regulations in general.

operations are conducted in the PRC, and are governed by PRC laws, rules, and regulations.

The PRC legal system is a civil law system

based on written statutes.

Unlike the common law system, prior court decisions may be cited for reference but have limited precedential

enacted laws, rules and regulations may not sufficiently cover all aspects of economic activities in China or may be subject to a significant

degree of interpretation by PRC regulatory agencies and courts.

Because these laws, rules and regulations are relatively new, and because

of the limited number of published decisions and the non-precedential nature of these decisions, and because the laws, rules and regulations

often give the relevant regulator significant discretion in how to enforce them, the interpretation and enforcement of these laws, rules

and regulations involve uncertainties and can be inconsistent and unpredictable.

Therefore, it is possible that our existing operations

may be found not to be in full compliance with relevant laws and regulations in the future.

In addition, the PRC legal system is based

in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive

As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation.

administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management

Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and

contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection

we enjoy than in more developed legal systems.

These uncertainties may impede our ability to enforce the contracts, including the VIE

agreements, and could materially and adversely affect our business, financial condition, and results of operations.

addition, the PRC government has recently announced its plans to enhance its regulatory oversight of Chinese companies listing overseas.

The Opinions on Intensifying Crack Down on Illegal Securities Activities issued on July 6, 2021, called for extraterritorial application

of China’s securities laws.

As the Opinions on Intensifying Crack Down on Illegal Securities Activities were recently issued, there

are great uncertainties with respect to the interpretation and implementation thereof.

The Chinese government may promulgate relevant

laws, internal rules and regulations that may impose additional and significant obligations and liabilities on overseas listed Chinese

companies regarding data security, cross-border data flow, and compliance with China’s securities laws.

These laws and regulations

can be complex and stringent, and many are subject to change and uncertain interpretation, which could result in claims, change to our

data and other business practices, regulatory investigations, penalties, increased cost of operations, or declines in user growth or engagement,

or otherwise affect our business.” It is uncertain whether or how these new laws, rules and regulations and the interpretation and

implementation thereof may affect SenlangBio.

The business of SenlangBio

may fall into the prohibited foreign investment category under currently effective PRC laws.

On March 15, 2019, the National

People’s Congress (“NPC”) promulgated the Foreign Investment Law, which took effect on January 1, 2020, and replaced

three existing laws regulating foreign investment in China, namely, the PRC Equity Joint Venture Law, the PRC Cooperative Joint Venture

Law and the Wholly Foreign-owned Enterprise Law, together with their implementation rules and ancillary regulations.

The Foreign Investment

Law grants foreign invested entities the same treatment as PRC domestic entities, except for those foreign invested entities that operate

in industries deemed to be either “restricted” or “prohibited” in the “negative list” published by

the State Council.

Sen Lang is a BVI company and the PRC Subsidiary is currently considered to be a foreign invested entity.

The latest version of the “negative

list,” namely, the Special Management Measures (Negative List) for the Access of Foreign Investment (2020), which became effective

on July 23, 2020, provides that foreign investment is prohibited in the development and application of human stem cells, genetic diagnosis

and treatment technology.

However, the PRC laws do not clarify the meaning of “development and application of human stem cells,

genetic diagnosis and treatment technology” and do not explain whether transactions involving a VIE Structure should be considered

as “investment” in the context of the prohibition of foreign investment.

SenlangBio’s main business is conducting R&D

and clinical transformation of immunotherapy cell therapy, which involves modifying the patient’s T-Cells genetically.

foregoing lack of clarity, the applicable rules could be interpreted in a way unfavorable to the business of SenlangBio.

In the context

of law enforcement, if the competent PRC authorities and courts interpret “development and application of human stem cells, genetic

diagnosis and treatment technology” broadly, the modification of T-Cells genetically could be considered as falling into the prohibited

foreign investment category.

If SenlangBio’s CAR-T cell therapies or other technologies that are being researched and developed

are deemed by relevant PRC regulatory agencies as falling into the category of “human stem cells, genetic diagnosis and treatment

technology,” SenlangBio would be prohibited from engaging in the research or development of such technologies.

In that event, Avalon

and the Sen Lang Beneficial Shareholders would have to restructure Avalon’s control over SenlangBio.

SenlangBio may also have to

forfeit its income derived from the research and development of such technologies.

Any of these occurrences may harm Avalon’s and

SenlangBio’s business, prospects, financial condition, and results of operations significantly.

uncertainties exist with respect to the interpretation and implementation of the PRC Foreign Investment Law, its implementing rules, Foreign

Investment Security Review Measures, other regulations and how they may impact the viability of the VIE structure, business, financial

condition, and results of operations.

VIE structure has been adopted by many China-based companies to obtain licenses and permits necessary to operate in industries that currently

are subject to restrictions on or prohibitions for foreign investment in China.

The Ministry of Commerce (“MOFCOM”) published

a discussion draft of the proposed Foreign Investment Law in January 2015, or the 2015 Draft Foreign Investment Law, according to which,

variable interest entities that are controlled via contractual arrangements would be deemed as foreign-invested enterprises if they are

ultimately “controlled” by foreign investors.

Even though such language did not appear in the official Foreign Investment

Law promulgated by the PRC State Council in 2019, there can be no assurance that the concept of “control” as reflected in

the 2015 Draft of the Foreign Investment Law, will not be reintroduced, or that the VIE structure adopted by us will not be deemed as

a method of foreign investment by other laws, regulations and rules.

In addition, as the 2019 Foreign Investment Law has a catch-all provision

that broadly defines “foreign investments” as those made by foreign investors in China through methods as specified in laws,

administrative regulations, or as stipulated by the PRC State Council, relevant government authorities may promulgate additional rules

and regulations as to the interpretation and implementation of the 2019 Foreign Investment Law.

Therefore, the use of a VIE Structure

could be considered a violation of the applicable PRC laws.

there are substantial uncertainties as to whether the VIE structure may be deemed as a method of foreign investment in a restricted industry

in the future.

If the VIE structure were to be deemed as a method of foreign investment under any future laws, regulations and rules,

and if any of our business operations were to fall under the “negative list” for foreign investment, the VIE structure may

be found to be in violation of any existing or future PRC laws, rules or regulations, then the relevant PRC regulatory authorities would

have broad discretion to take action in dealing with these violations or failures, including revoking the business and operating licenses

of SenlangBio, requiring it to discontinue or restrict its operations, restricting its right to collect revenue, requiring it to restructure

our operations or taking other regulatory or enforcement actions against it.

The imposition of any of these measures could result in a

material adverse effect on SenlangBio’s ability to conduct all or any portion of its business operations.

In addition, it is unclear

what impact the PRC government actions would have on us and on our ability to consolidate the financial results of SenlangBio in our consolidated

financial statements, if the PRC government authorities were to find our legal structure and contractual arrangements to be in violation

of PRC laws, rules, and regulations.

If the imposition of any of these government actions causes us to lose our right to direct the activities

of SenlangBio or otherwise separate from SenlangBio and if we are not able to restructure our ownership structure and operations in a

satisfactory manner, we would no longer be able to consolidate the financial results of SenlangBio in our consolidated financial statements.

Any of these events would have a material adverse effect on our business, financial condition, and results of operations.

on December 19, 2020, the National Development and Reform Commission and MOFCOM promulgated the Foreign Investment Security Review Measures,

which took effect on January 18, 2021.

There are great uncertainties with respect to its interpretation and implementation.

Foreign Investment Security Review Measures, investments in military, national defense-related areas or in locations in proximity to military

facilities, or investments that would result in acquiring the actual control of assets in certain key sectors, such as critical agricultural

products, energy and resources, equipment manufacturing, infrastructure, transport, cultural products and services, IT, Internet products

and services, financial services and technology sectors, are required to be approved by designated governmental authorities in advance.

Since SenlangBio’s main business is conducting R&D and clinical transformation of immunotherapy cell therapy, we cannot rule

out the possibility that investment in SenlangBio may be regarded as “investment in technology sectors,” which would require

approval from governmental authorities.

Moreover, because the term “investment through other means” is not clearly defined

under the Foreign Investment Security Review Measures, we cannot rule out the possibility that control through contractual arrangement

may be regarded as a form of actual control and therefore require approval from the competent governmental authority.

The filing or change of the medical

institution practice license of SenlangBio Clinical Laboratory may be affected by the VIE Structure.

As SenlangBio Clinical Laboratory is a medical

institution under the PRC laws, its operation is subject to the PRC regulation of foreign investment in the area of medical institution,

which provides that a foreign investor can acquire 70% (to the highest extent) of the equity interests in a PRC medical institution.

The relevant PRC laws also provide that the related government authority shall not approve any application of licenses/permits if the

application is related to a company failing to comply with PRC foreign investment regulation.

Therefore, if the competent PRC authority

responsible for the registration of the medical institution practice license of SenlangBio Clinical Laboratory adopts a broad understanding

of foreign investment rules that controlling via agreements can be deemed as a way of investment, the authority may disapprove SenlangBio

Clinical Laboratory’s application in relation to its medical institution practice license, including any extension of such license.

In the worst case, theoretically, the competent authorities may deem the VIE Agreements unenforceable because they are in violation of

the PRC laws.

In that event, SenlangBio Clinical Laboratory would not be qualified to conduct any business of testing of immunology,

serology and molecular genetics specialties for patients, including hematology-tumor diagnostics and testing prior to clinical trials

for cell therapy, which would result in the loss of the license and thereby the loss of income to SenlangBio from this business.

in the policies of the PRC government could have a significant impact upon the business we may be able to conduct in the PRC and the

profitability of our business.

The PRC’s economy is in a transition from a

planned economy to a market-oriented economy subject to five-year and annual plans adopted by the government that set national economic

development goals.

Policies of the PRC government can have significant effects on the economic conditions within the PRC.

no assurance that the PRC government will continue to support a market orientated economy.

A change in policies by the PRC government

could adversely affect our interests by, among other factors:

changes in laws, regulations or the interpretation thereof, confiscatory

taxation, restrictions on currency conversion, imports or sources of supplies, or the expropriation or nationalization of private enterprises.

Although the PRC government has been pursuing economic reform policies for more than two decades, there is no assurance that the government

will continue to pursue such policies or that such policies may not be significantly altered, especially in the event of a change in leadership,

social or political disruption, or other circumstances affecting the PRC’s political, economic and social environment.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1A. Risk Factors